
SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation.
“Agitation manifests in the course of AD progression in almost all affected patients, increasing patients’ suffering and burden of care,” reads a press release. “This Phase IIa clinical trial is an open-label study, which includes 20 patients diagnosed with AD and agitation, to evaluate the safety, tolerability, and efficacy trends of twice daily oral administration of SCI-110.”